SYIN.US Synbio International, Inc.
- Market cap
- USD 81.8K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is SYIN.US undervalued?
Graham numberThe Graham number of Synbio International, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Synbio International, Inc. fundamental analysis
No fundamental analysis for Synbio International, Inc. yet.
Synbio International, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Synbio International, Inc.
Synbio International, Inc. engages in the development and clinical validation of artificial intelligence-based medical technologies to enhance diagnostic accuracy and improve patient outcomes. It also markets nutraceutical products that support long-term health, wellness, and disease management. The company was formerly known as Natural Harmony Foods, Inc. and changed its name to Synbio International, Inc. in July 2024. Synbio International, Inc. was incorporated in 2002 and…
Full company profileSynbio International, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Synbio International, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2005 | 2006 | 2007 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 114K | 115K | 98.6K | - | - |
| Gross Profit | 26.6K | 25.0K | 14.7K | - | - |
| Operating Income | -211K | -538K | -432K | -109K | -424K |
| EBITDA | -200K | -529K | -432K | -109K | -424K |
| Net Income | -211K | -538K | -432K | -128K | -458K |
| EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 774K | 538K | 146K | 111K | 40.9K |
| Total Liabilities | 493K | 93.1K | 229K | 794K | 896K |
| Shareholders' Equity | 281K | 445K | -83.0K | -682K | -855K |
| Cash & Short-term Investments | 12.4K | 48.9K | 21.7K | 1.32K | 7.85K |
| Total Debt | 375K | 68.6K | 55.1K | 152K | 161K |
| Cash Flow | |||||
| Operating Cash Flow | -98.7K | -364K | -320K | -88.4K | -93.4K |
| Capital Expenditure | 1.61K | 0.00 | 3.00 | 0.00 | 18.00 |
| Free Cash Flow | -100K | -364K | -320K | -88.4K | -93.4K |
| Ratios | |||||
| ROE | -75.3% | -120.9% | - | - | - |
| ROA | -27.3% | -100.0% | -295.7% | -114.5% | -1,120.1% |
| Net Profit Margin | -185.2% | -468.0% | -438.8% | - | - |
| Debt to Equity | 1.34x | 0.15x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Synbio International, Inc. dividends
Synbio International, Inc. has not paid dividends in the last 4 fiscal years.
Who owns Synbio International, Inc.
Ownership data of Synbio International, Inc. is not available yet.
Synbio International, Inc. company profile
- Company name
- Synbio International, Inc.
- Ticker
- SYIN.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Shell Companies
- Employees
- 1
- Fiscal year end
- December
- Address
- 30 N Gould St., Ste 5835, Sheridan, WY, United States, 82801
- Phone
- 307-278-1360
- Website
- synbiointl.com
About Synbio International, Inc.
Synbio International, Inc. engages in the development and clinical validation of artificial intelligence-based medical technologies to enhance diagnostic accuracy and improve patient outcomes. It also markets nutraceutical products that support long-term health, wellness, and disease management. The company was formerly known as Natural Harmony Foods, Inc. and changed its name to Synbio International, Inc. in July 2024. Synbio International, Inc. was incorporated in 2002 and is based in Sheridan, Wyoming.
Synbio International, Inc. management
2- Mr. Giacinto Claudio SolitarioChairman, CEO, MD, President, Secretary & Treasurer · born 1960
- Ms. Desiree Cain CPA, M.B.A.CFO & Director